Review article

Lacosamide as monotherapy in focal seizure: Literature review

Kishore R. Sonkusare*, Hanmant V. Barkate

Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India

ARTICLE INFO

Article history:
Received 27 June 2016
Accepted 21 December 2016
Available online 12 January 2017

Key words:
Lacosamide
Monotherapy
Historical controlled trial
Focal seizure

ABSTRACT

Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure.

© 2016 Indian Epilepsy Society. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.

1. Introduction

Epilepsy is a brain disorder defined by at least two unprovoked (or reflex) seizures occurring >24h apart and one unprovoked seizure and a probability of further seizures in next 10 years. Epilepsy is clinically presented as recurrent seizures due to abnormal synchronous or excessive neuronal discharge in the brain.1 Seizures are classified as generalized seizures (synchronized discharges involving both hemispheres), or focal seizures (previously called partial-onset seizures) involving one cerebral hemisphere.2 The worldwide prevalence of epilepsy is between 4 and 10 per 1000 population,3 while in India it is 5.59 per 1000 population with equally distributed between men and women or urban and rural region.4

The goal of pharmacotherapy with antiepileptic drugs (AEDs) is to reduce the frequency of epileptic seizures and achieve a seizure-free state. There are evidences that the majority of seizure patients can achieve seizure freedom with monotherapy, but only four AEDs i.e. felbamate, lamotrigine, oxcarbazepine, and topiramate are being approved by United States Food and Drug Administration (USFDA) as monotherapy, and only topiramate and oxcarbazepine have an indication for initial monotherapy.6–9 Another 4 drugs have been considered as conversion to monotherapy in U.S.: lamotrigine extended-release, levetiracetam extended-release, pregabalin and eslicarbazepine.10–13

Lacosamide (R-enantiomer of 2-acetamido-N-benzyl-3-methoxypropionamide, previously known as harkoseride or ADD 234037) is a newer approved AED characterized by his novel pharmacodynamic profile.14 Lacosamide (LCM) was approved in 2008 by the European Medicines Agency (EMEA)15 and by the US

* Corresponding author at: Intas Pharmaceuticals Ltd. Premier House 1, Off Gurudwara, SG Highway Bodakdev, Ahmedabad 380054, India.
E-mail address: kishore_sonkusare@intaspharma.com (K.R. Sonkusare).

http://dx.doi.org/10.1016/j.ijep.2016.12.006
2213-6320/© 2016 Indian Epilepsy Society. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.
FDA16 as adjunctive treatment in patient aged >16 years (EMEA) and 17 years (FDA) with focal seizures with or without generalization and is newly licensed in 2014 by US FDA16 for use as monotherapy in adults (aged >17 years) with focal seizures. Oral lacosamide is available in 50, 100, 150 and 200-mg in tablet form and 10 mg/ml in oral solution. An intravenous formulation (10 mg/ml) is also available for short-term replacement of oral LCM but it is not currently approved for status epilepticus (SE).16

This article reviews the therapeutic use of lacosamide as monotherapy in patients with focal seizures along with an overview of its novel pharmacological properties.

2. Pharmacodynamic properties

The specific mechanism by which LCM exerts its antiepileptic effects in humans is not yet known.16 Recent study results suggest that LCM has a dual mode of action responsible for its anticonvulsant and analgesic activity.14 LCM has an effect on the voltage-gated sodium channels (VGSCs). LCM has unique ability to with the slow inactivation of VGSCs with no role in fast inactivation, unlike other AEDs, such as carbamazepine, phenytoin and lamotrigine inhibit both slow and fast inactivation of VGSCs.17

This enhancement of slow inactivation of sodium channels coupled with neuronal hyperexcitability by normalizing activation thresholds and decreasing pathophysiological neuronal activity.18

Lacosamide also exerts its action by binding to collapsing-response mediator protein-2 (CRMP2), a phosphoprotein that is involved in neuronal differentiation and control of axonal growth.19,20 However, this binding has recently been debated as in vitro study has advocated that LCM does not specifically bind to CRMP-2.21

3. Pharmacokinetic properties

Following oral administration, LCM is rapidly and completely absorbed after single dose with negligible first pass effect with absolute bioavailability ~100%. Maximum LCM serum concentration is attained in 1–4 hours after oral administration and immediately after intravenous infusion. There is no effect of food on the rate and extent of absorption. Steady-state plasma levels (C₀ss) are achieved after 3 days of twice daily oral administration. The plasma concentration of LCM shows linear and proportional increase with increasing oral and intravenous doses up to 800 and 300 mg, respectively, with low inter- and intra-subject variability. Intravenous infusion of LCM 200 mg is bioequivalent to the same dose administered orally in healthy volunteers. A single oral dose of 200 mg approximates steady-state concentrations which is comparable to the oral dose of 100 mg twice a day.16,20,22,23

Lacosamide exhibits negligible plasma protein binding (<15%) and has a volume of distribution (~0.6 L/kg) equal to total body water. LCM is mainly excreted from the systemic circulation by kidney and biotransformation. After oral and intravenous administration, approximately 95% of radioactivity administered is excreted in the urine mainly as unchanged lacosamide (~40% of the dose), its O-desmethyl metabolite (~30%), and ~20% as a structurally unknown polar fraction and small amount (~<0.5%) in the feces. CYP3A4, CYP2C9, and CYP2C19 isoforms are mainly involved in the metabolism of O-desmethyl metabolite. The elimination half-life of the unchanged lacosamide is ~13 h and its O-desmethyl metabolite is 15–23 hours. Elimination is not altered by any type of dosing, multiple dosing or intravenous administration.16,20,22,23

Lacosamide has shown no pharmacokinetic differences in special population like age (>65 years), gender, race or CYP2C19 polymorphism.19 There is no clinically significant drug-drug interaction of lacosamide with commonly used AEDs like valproic acid, carbamazepine, gabapentin, levetiracetam, phenytoin) and drugs that undergo CYP-mediated biotransformation like warfarin, midazolam, omeprazole (Table 1).22

4. Efficacy of Lacosamide as monotherapy

Lacosamide has been approved for monotherapy by the US FDA based on historical controlled trial by Wechsler RT et al.24 in 2014 and its efficacy as monotherapy has been established in prospective,25 retrospective study26 each and data presented in abstract format at the conference.27–29

The efficacy of conversion from stable dosages of 1–2 AEDs to oral lacosamide monotherapy was evaluated in patients (age 16–70 years) in a historical-cohort controlled, double-blind study [ALEX-MT] (A Lacosamide EXchange to Monotherapy Trial) conducted by Wechsler et al.25 Those patients experiencing 2–40 focal seizures per 28 days during the 8-week prospective baseline were eligible for randomization to lacosamide 400 mg (n = 319) or 300 mg/day in 3:1 proportion. A 300 mg/day treatment group (n = 106) was included to blind treatment group (400 mg/day). Study was conducted in two phases: 3 week titration phase and 16 week lacosamide maintenance phase (6 week withdrawal phase in which background AEDs has been withdrawn and 10 week monotherapy phase). The primary efficacy outcome was the percentage of patients receiving lacosamide 400 mg/day who met ≥1 of the exit criteria (Table 2) by day 112 of the maintenance phase in the full analysis set (n = 284; i.e. patients who completed the titration phase and initiated withdrawal phase) compared with the prespecified historical-control exit percentage (65.3%). Analyses were done by using Kaplan–Meier estimates.

By day 112, the percentage of patients in the lacosamide 400 mg/day monotherapy group meeting at least one exit criterion was 30.0% (95% CI 24.6–35.5%) which was superior than historical control, as the upper limit of the 95% confidence interval was lower than the historical-control exit percentage (35.5% versus 65.3%). The mean time to exit due to meeting at least one exit criterion during maintenance phase was 45.0 days in the lacosamide 400 mg/day monotherapy group. Median duration of lacosamide monotherapy 400 mg/day treatment was 71 days during maintenance phase. In addition, Patient’s Global Impression of Change

Table 1

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Absolute bioavailability</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tmax</td>
<td>1–4 h</td>
<td></td>
</tr>
<tr>
<td>Cmax</td>
<td>8.7 ± 1.8 µg/ml</td>
<td>100%</td>
</tr>
<tr>
<td>Elimination t1/2</td>
<td>13 h</td>
<td></td>
</tr>
<tr>
<td>Plasma protein binding</td>
<td>15%</td>
<td></td>
</tr>
<tr>
<td>Volume of distribution</td>
<td>0.61 L/kg</td>
<td></td>
</tr>
<tr>
<td>Effect of food on absorption</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Route of elimination</td>
<td>Renal</td>
<td></td>
</tr>
<tr>
<td>Significant drug interaction with other antiepileptic drugs or with warfarin, midazolam, metformin, omeprazole, digoxin, estrogen</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
In a prospective study conducted by Lattanzi S et al., lacosamide as conversion monotherapy was evaluated for 1 year in patients with focal seizure. Patients who achieved 1 year seizure freedom on lacosamide add-on therapy, then converted to lacosamide monotherapy (350–400 mg/day) were followed up for 1 year (n = 58). Primary outcome parameters were the seizure freedom at 1 year as monotherapy from withdrawal of background AEDs and LCM monotherapy maintenance for all seizure types.

In a post-hoc analysis presented in 68th Annual Meeting of the American Epilepsy Society, conversion monotherapy to lacosamide was found effective in both 300 mg and 400 mg/day group, ≥50%, ≥75% & 100% reductions in seizure frequency during monotherapy maintenance phase were seen in 60.7, 34.3 and 14.9% patients respectively.

In another post hoc analysis presented in 68th Annual Meeting of the American Epilepsy Society, conversion monotherapy to lacosamide was found effective in both 300 mg and 400 mg/day group, ≥50% reduction in seizure frequency/28 days was seen in 50, 42 and 39% in patients with 0–5 (n = 100), >5–15 (n = 120) and 15 years (n = 205) duration of epilepsy respectively while seizure-free rates was noted in respective 12, 12 and 6% patients during 10 weeks monotherapy phase. During monotherapy phase in patients previously discontinued 0, 1, 2 or ≥AEDs before study entry (n = 85, 72, 73 and 195, respectively), ≥50% responder rates were noted in 45, 42, 49 and 39% patients respectively, and respective seizure-free rates were 13, 14, 6 and 7%.

The median focal seizure frequency per 28 days during the baseline phase decreased during lacosamide maintenance phase by 51% (simple seizure) and 60% (complex seizure) for all seizures. This post-hoc analysis suggested that seizure frequency across all patients was reduced during titration and was maintained during withdrawal of background AEDs and LCM monotherapy maintenance for all seizure types.

In a retrospective study conducted by Giráldez BG et al., lacosamide monotherapy was generally well tolerated in patients with focal seizure, with the majority of adverse events reported were mild or moderate in intensity. In historical controlled study treatment emergent adverse events (TEAE) was noted in 84.5% patients, mostly seen during titration phase out of which 16.9% patients discontinued the lacosamide therapy due to TEAE. Serious adverse events were reported in 4% patients, which were mainly unrelated to lacosamide therapy; convulsion was the only serious adverse effect occurred in more than 1 patient (n = 5 patients).

One retrospective study conducted by Giráldez BG et al. has evaluated efficacy and tolerability in patients with focal seizure on lacosamide monotherapy (mean dose 252.7 mg/day). Patients were divided in 2 groups: Group 1- naïve to AED therapy (n = 18) and Group 2- previously been treated with AEDs (n = 48). Seizure-free rates and mean seizure frequency reduction were analyzed during complete follow up and after 6 and 12 months of stable maintenance dose. Mean duration of monotherapy was 15.5 months. Overall seizure free rate was seen in 63.8% (72.2% in Group 1 & 60.4% in Group 2) while the seizure-frequency at 6 and 12 months follow up were 77.6% and 72.3% respectively. Mean seizure frequency reduction seen in the both group was 74.8% and 75.6% at 6 and 12 months respectively (P < 0.001).

Table 2
Predefined exit criteria.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Wechsler RT</th>
<th>Ryvlin P</th>
<th>Lattanzi S</th>
<th>Giráldez BG</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>LCM 400 mg (n = 319) &amp; 300 mg (n = 108)</td>
<td>LCM 400 &amp; 300 mg (n = 425)</td>
<td>LCM 400 mg (n = 58)</td>
<td>LCM 400 mg (n = 114)</td>
</tr>
<tr>
<td>≥50% reduction in seizure frequency (% patients)</td>
<td>60.7%</td>
<td>• 50% with 0–5 years[^4]</td>
<td>• 42% with 5–15 years[^4]</td>
<td>55.2%</td>
</tr>
<tr>
<td>Seizure freedom (% patients)</td>
<td>14.9%</td>
<td>• 12% with 0–5 years[^4]</td>
<td>• 12% with 5–15 years[^4]</td>
<td>63.6%</td>
</tr>
</tbody>
</table>

[^4] Patients with total duration on epilepsy (years).
convulsion, somnolence, and fatigue. The most common TEAEs which lead to discontinuation of losacamide monotherapy were convulsion, dizziness and fatigue.24–26,28

6. Summary and Conclusion

Losacamide is a novel AED that has been approved as monotherapy in patients of 17 years of age or older with focal seizures with or without secondary generalization in 2014. Losacamide has a favorable pharmacokinetic profile that includes a relatively long half-life (13 h) which allows for twice-daily administration; has very low plasma protein binding (15%), 100% bioavailability that is not affected by concomitant food, little potential for significant drug–drug interactions and easy switch over from oral to intravenous therapy for short-term at the same dosage and vice versa, which may be mainly helpful in situations where oral therapy is not suitable.

With respect to efficacy, historical controlled study has demonstrated superiority to that of a historical-control cohort converting from previous AED therapy. Several prospective and retrospective studies confirmed the efficacy of losacamide for focal seizure control with retention rate was seen in more than two thirds patients during 1 year follow up period. Losacamide was well tolerated. Dizziness was the most common adverse event (AE), followed by headache, nausea, convulsion and fatigue. All these AE's were reported during titration phase and were of mild to moderate intensity. Convulsion and dizziness were commonly responsible for drug discontinuation.

In conclusion, with good pharmacokinetic profile of losacamide, proven efficacy and good tolerability as monotherapy, losacamide can be a useful and welcome addition to the existing therapy of focal seizure.

References

5. Shneker BF, Fountain NB. Epilepsy Dis Mon. 2003;49(July (7)):426–478.
22. Scott LJ. Losacamide a review in focal seizures in patients with epilepsy. Drugs. 2015;75(December (18)):2143–2154.